Your Egg Quality Is Declining. Your Genes May Explain Why.

MTHFR is the enzyme that converts folate into methylenetetrahydrofolate, the active form your cells use to methylate DNA. This methylation is the chemical process that silences genes you don’t need and activates genes you do. In a developing embryo, methylation is the difference between normal development and developmental errors.

The C677T variant, carried by roughly 40% of people with European ancestry, reduces MTHFR enzyme activity by 40-70%. That means your cells are converting dietary folate into usable methylation substrates at a fraction of the rate they should. Even more critical: your eggs are developing and methylating their DNA throughout your reproductive years. If your MTHFR is compromised, every egg produced carries the consequences of that impaired methylation.

You may notice recurrent miscarriages, slow embryo development, or a pattern of pregnancies that stop progressing around week 8-10, when fetal DNA methylation patterns become critical. Blood tests show your folate is normal because they’re not measuring the active form. Your homocysteine may be elevated, a sign methylation is struggling. You may have been told you have “unexplained infertility” or “recurrent pregnancy loss,” when the explanation was sitting in your DNA all along.

FSHR is the receptor on your ovarian follicles that listens for FSH, the hormone signaling your eggs to grow. When FSH binds to FSHR, it tells the follicle to develop and mature. Without this signal, no eggs develop at all. Your ovarian reserve depends on having functional FSHR receptors.

The N680S variant determines FSHR efficiency. Women with the S/S genotype, present in roughly 10-15% of the population, have a less sensitive FSH receptor. This means your follicles require higher FSH levels to respond, and they respond less robustly overall. You may have normal FSH levels but poor follicle development, or require unusually high FSH doses in an IVF cycle.

You’ve probably noticed that your ovarian response to stimulation is unpredictable or underwhelming. Your doctor increases FSH doses, and you still don’t recruit many eggs. Other women with your same starting FSH get more eggs at lower doses. Your fertility clinician might describe you as a “poor responder” without realizing your genetics are the reason. This variant also predicts your natural ovarian reserve: if you carry S/S, your ovarian reserve declined faster with age.

ESR1 is the estrogen receptor in your endometrium, the uterine lining where an embryo implants. Estrogen signals your endometrium to thicken, proliferate, and prepare for pregnancy. But this only works if your endometrial cells can hear the estrogen signal. ESR1 variants determine how sensitive your endometrium is to estrogen.

The PvuII and XbaI variants affect estrogen receptor expression. Roughly 40% of women carry variants that reduce endometrial estrogen receptor sensitivity. Your endometrium may look thick on ultrasound but not be biologically receptive to an embryo because your receptor sensitivity is compromised. This is why you can have a textbook-perfect endometrial thickness and still have failed implantations.

You’ve experienced transfer after transfer where the embryo looks good, the lining looks good, and nothing happens. Your doctor says implantation failure is “unexplained.” But if your ESR1 receptor sensitivity is low, your endometrium is not mounting a proper decidualization response. You need more estrogen, not more embryos. You may feel frustration that standard hormone support isn’t working because it’s calibrated for average receptor sensitivity, not yours.

COMT is the enzyme that breaks down catecholamines (dopamine, norepinephrine, epinephrine) and estrogen. When COMT works efficiently, it clears excess estrogen quickly, preventing buildup. When COMT is slow, estrogen accumulates in your blood and tissues.

The Val158Met variant creates two COMT types: fast metabolizers and slow metabolizers. Roughly 25% of people with European ancestry are homozygous for the slow variant. Slow COMT means your estrogen levels stay elevated longer, creating a hormonal environment that promotes endometriosis, PCOS, and follicle dysfunction. If you’re a slow metabolizer, every menstrual cycle amplifies estrogen load in your tissues.

You may have noticed endometriosis, painful periods, or adenomyosis on imaging. You may have PCOS-like symptoms: irregular cycles, androgen elevation, insulin resistance, despite not meeting all PCOS criteria. Your estrogen feels persistently elevated even though your lab values are in the normal range. Your ovaries don’t respond as well during high-estrogen phases of your cycle. The longer estrogen persists in your system, the more it drives inflammation and reduces egg quality.

VDR is the vitamin D receptor, the protein that lets your cells hear vitamin D signals. Vitamin D is not just for bone health; it’s a critical signaling molecule for immune regulation, inflammation control, and reproductive function. Your ovaries express VDR throughout the menstrual cycle. Your endometrium expresses VDR during the window of implantation.

VDR variants (FokI, BsmI, ApaI, TaqI) determine how sensitive your cells are to vitamin D. If you carry variants that reduce VDR sensitivity, even normal vitamin D blood levels may not provide adequate signaling to your reproductive tissues. VDR variants are associated with reduced ovarian reserve, lower egg yield in IVF cycles, and higher rates of implantation failure and miscarriage. Roughly 40-50% of women carry at least one VDR variant that reduces function.

You may have been told your vitamin D is fine based on a blood test. But if your VDR is inefficient, fine is not enough. Your ovaries need robust vitamin D signaling. Your endometrium needs it during implantation. You may notice that despite supplementing vitamin D, your fertility markers don’t improve, or that low vitamin D seems to coincide with cycle irregularity and poor egg development.

FMR1 is the fragile X mental retardation 1 gene. The full mutation causes fragile X syndrome. But a premutation, a smaller expansion of the same repeats, is associated with premature ovarian insufficiency (POI) in women. Roughly 1 in 250 females carry an FMR1 premutation (55-200 CGG repeats).

Women with FMR1 premutation experience accelerated ovarian aging. Their ovarian reserve declines faster than expected for their chronological age. FMR1 premutation carriers often experience menopause 5-15 years earlier than average, and many experience earlier-than-expected decline in egg quality and quantity in their late 30s and 40s. FSH levels rise more quickly. Ovarian response to stimulation diminishes. The biological mechanism involves impaired mitochondrial function in your oocytes.

If you’re experiencing unexpectedly rapid decline in your ovarian reserve, especially if you’re in your late 30s or 40s, FMR1 premutation status is critical information. You may have thought your egg decline was age-related, when it’s actually genetically accelerated. You may have been told to hurry with family planning, but without the genetic context, the urgency seemed vague. If you carry FMR1 premutation, understanding this changes your reproductive timeline and your strategy.